Seiji Mori

Title: Seiji Mori: Innovator in FGF Signaling Research

Introduction

Seiji Mori is a prominent inventor based in Houston, TX (US). He has made significant contributions to the field of cellular signaling, particularly through his innovative patents. With a total of 3 patents, Mori's work focuses on developing antagonists that can suppress FGF-mediated cellular signaling.

Latest Patents

Mori's latest patents include groundbreaking inventions such as "Dominant-negative FGF2 antagonists." This invention provides dominant negative mutants of FGF2, which are designed to suppress FGF-mediated cellular signaling. Additionally, he has developed compositions and methods related to anti-FGF agents. This invention involves an isolated amino acid that acts as an antagonist to FGF signaling, comprising a portion of the FGF protein amino acid sequence, with specific mutations in the integrin αvβ3 binding region or the FGFR binding region of FGF-1.

Career Highlights

Seiji Mori is affiliated with the University of California, where he continues to advance research in his field. His work has garnered attention for its potential applications in therapeutic settings, particularly in diseases where FGF signaling plays a critical role.

Collaborations

Mori has collaborated with notable colleagues, including Yoshikazu Takada and Yoko Takada. These collaborations have further enriched his research and contributed to the development of innovative solutions in cellular signaling.

Conclusion

Seiji Mori's contributions to the field of FGF signaling through his patents highlight his role as an influential inventor. His work not only advances scientific understanding but also opens new avenues for therapeutic interventions.